Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
AAR CORP. announced it has entered into a definitive agreement to acquire a 65% controlling interest in MRO Holdings, Inc. at an implied enterprise value of approximately $4.0 billion. To fund the transaction, the company launched a private offering of $1.915 billion in senior notes, consisting of $955 million due 2031 and $960 million due 2034.
Landstar System President & CEO Frank A. Lonegro Buys $715K of Stock
Frank A. Lonegro, President & CEO, bought 5,000 shares of Landstar System Inc at $142.92 a share, worth $715K in total on Oct 30, 2026. Shares held after the trade: 28,110 (+21.6%).
Intrusion $4M Debt Financing with Streeterville Capital, LLC
Intrusion Inc. entered into an exchange agreement with Streeterville Capital, LLC to settle $4.0 million in aggregate principal debt from two existing secured promissory notes. The debt was exchanged for 4,000 shares of newly designated Series B Preferred Stock, resulting in the cancellation of the partitioned debt obligations. The transaction was conducted as a debt-for-equity exchange under Section 3(a)(9) of the Securities Act.
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) provided a status update on its pending business combination with Electra Vehicles, Inc., including a new investor presentation and a newsletter detailing Electra's recent developments. The filing highlights Electra's new partnership with Westbrook Racing as its Official Battery Intelligence Partner and its participation in several global industry conferences.
Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.
Strive, Inc. provided an operational update disclosing the purchase of 124 bitcoin for approximately $10 million between October 24 and October 30, 2026. The company also reported updated treasury holdings, including 43,124 total bitcoin and $490.4 million in cash and cash equivalents as of October 30, 2026.
Marriott International reported net income of $794 million for the third quarter of 2026, an increase from $728 million in the prior year period. Total revenues grew to $7.01 billion, driven by higher franchise and management fees, while the company continued significant shareholder returns through $3.08 billion in treasury stock purchases during the first nine months of the year.
CorMedix provided a business update reporting a cash position of approximately $355 million as of September 30, 2026, and reaffirmed its full-year 2026 revenue guidance. The company also addressed the CMS 2027 ESRD PPS final rule regarding DefenCath reimbursement, projecting that the average 2027 Add-on rate will be more than double the current rate.
Loews Corporation reported net income of $306 million for the third quarter of 2026, down from $504 million in the prior year period, primarily due to higher insurance claims and a $222 million re-measurement loss. Total assets decreased slightly to $85.3 billion as of September 30, 2026, while the company continued its capital return strategy through $348 million in treasury stock purchases year-to-date.
Lightbridge Corporation reported third quarter 2026 financial results and provided a business update, including its selection for the DOE Nuclear Energy Launch Pad INL program. The company also secured loop irradiation testing for its fuel rodlets at the Idaho National Laboratory and is currently conducting post-irradiation examinations of its first fuel samples.
“Selection for the Launch Pad INL program can help to accelerate our commercialization plan. Rather than waiting for a commercial fuel factory to be licensed before we could manufacture lead test assemblies, we now have a pathway toward DOE authorization for a dedicated Pilot Factory at INL, and we are negotiating the agreements and project scope with NRIC and INL.”
Seth Grae, Chairman and Chief Executive Officer
“We believe the loop irradiation will allow us to go from the ATR directly to lead test assemblies in commercial nuclear power plants, rather than first deploying segments of fuel rods and lead test rods in commercial reactors.”
Steakholder Foods Insider Yaron Kaiser Buys $23.2K of Stock
Yaron Kaiser bought 56,432 shares of Steakholder Foods Ltd. at $0.4064 to $0.4162 a share (average $0.4109) in 2 transactions, worth $23.2K in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 67,604 (+63.0%).
Cipher Digital reported Q3 2026 results, marking a strategic milestone with the recognition of its first HPC lease revenue at the Black Pearl campus. The company expanded its Barber Lake lease to a 20-year term with a leading AI lab, increasing total contracted revenue at the site to $9.1 billion. Additionally, Cipher received conditional base load classification for 1 GW at its Colchis site and commenced development of lateral pipelines to support up to 2.5 GW of on-site generation.
“Cipher was built for this market, and this quarter we took important steps to strengthen our position for the long term. The decisions we made early on about who we partner with, how we structure our projects, how we navigate a dynamic regulatory environment and how we engage with our communities were made for exactly these conditions. Demand for compute is growing, and our relationships with leading hyperscalers and AI labs are deepening. We are adding new capacity to our pipeline, investing earlier in every project and advancing design work before committing to new leases, so we are well positioned for our next phase of growth.”
Xcel Energy Inc. announced a private offering of $2.0 billion in convertible senior notes due 2027, with an additional $300 million overallotment option for purchasers. The company intends to use the proceeds to repay short-term debt, including commercial paper and a 364-day delayed draw term loan, and for general corporate purposes.
uniQure announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington’s disease, for review under the Accelerated Approval pathway. The FDA granted the application Priority Review with a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting to discuss the application.
The FDA granted accelerated approval for INOVIO's VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP). This represents the first U.S. FDA-approved DNA medicine and validates INOVIO's platform technology, with a commercial launch expected in Q1 2027.
“With the approval of VOCERYQ, we believe our DNA medicine platform has the potential to transform the treatment paradigm for RRP by offering a patient-centric treatment option. VOCERYQ is designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP.”
Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
Flowco Holdings Inc. announced that its Board of Directors approved a $150 million increase to its existing share repurchase program, bringing the total authorization to $200 million. The program allows for opportunistic repurchases of Class A common stock in the open market or through private transactions and has no expiration date.
Lumentum reported Q1 fiscal 2027 net revenue of $1.26 billion, a 136.5% increase year-over-year, driven by strong demand for pump lasers and optical circuit switches. The company also announced a major NPO/CPO win with purchase commitments exceeding $5 billion and provided strong Q2 guidance reflecting continued sequential growth.
Term
Q1 2027
“Lumentum built on its strong momentum in the first fiscal quarter of 2027, delivering growth across all our businesses, with pump lasers and optical circuit switches (OCS) being the leading contributors. During the quarter, we secured our second major NPO/CPO win, backed by purchase commitments exceeding $5 billion. Additionally, our OCS demand visibility has expanded significantly in recent months, positioning optical switching to become a multi-billion-dollar annual revenue stream. Finally, we continue to see strength in our cloud modules business which is showing improvement on the gross margin line.”
Michael Hurlston, President and CEO
“Looking ahead, we anticipate adding approximately $350 million in sequential growth in our second quarter, a figure greater than the quarterly revenue of the whole company just two years ago. Furthermore, we project our second quarter operating margin to exceed 45 percent.”
Boardwalk Pipeline Partners, LP reported net income of $461.1 million for the nine months ended September 30, 2026, a slight increase from $454.3 million in the prior year period. Total operating revenues grew to $1.81 billion, driven by higher transportation and product sales, while the company significantly increased capital expenditures to $550.2 million.
Seaport Therapeutics is a clinical-stage therapeutics company that recently transitioned to public markets, reporting 53,530,550 shares of voting common stock outstanding as of October 2026. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, focusing on advancing its clinical pipeline and research programs.
Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.
“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”
Krish S. Krishnan, Chairman and Chief Executive Officer
Krystal Biotech reported a strong third quarter in 2026, with product revenue increasing to $127.3 million compared to $97.8 million in the prior year. Net income for the nine months ended September 30, 2026, rose to $173.8 million, supported by significant growth in cash and investments totaling over $1.19 billion.
Axsome Therapeutics reported Q3 2026 financial results with total net product revenue of $259.7 million, a 52% year-over-year increase driven by strong sales of Auvelity and Sunosi. The company significantly narrowed its net loss to $12.9 million compared to $47.2 million in the prior year period, surpassing a $1 billion annual revenue run rate.
Term
Q3 2026
“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation.”
Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics
TripAdvisor Divestiture to American Express Travel Related Services Company, Inc. for $700M
Tripadvisor completed the sale of its European online restaurant reservation platform, TheFork, to American Express for $700 million in cash. The deal includes a 12-month transition services agreement to facilitate the separation of the business. Tripadvisor expects to discuss the impact of this significant disposition during its Q3 2026 earnings call.
Value
$700M
Counterparty
American Express Travel Related Services Company, Inc.
Tempus AI reported total net revenue of $411.5 million for the third quarter of 2026, a 23% increase year-over-year, driven by growth in both Diagnostics and Data and Applications segments. The company significantly narrowed its net loss to $14.9 million compared to $80.0 million in the prior year period, aided by a substantial $108.9 million gain on marketable equity securities.
Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
Marriott International reported third quarter 2026 results with worldwide RevPAR increasing 6.5% and net income reaching $794 million. The company achieved record development pipeline growth with over 634,000 rooms and returned $1.3 billion to shareholders through stock repurchases during the quarter.
Term
3 years
“Our excellent third quarter results reflected continued momentum across our business, the benefits of our global scale, and the power of our brands and revenue engines. Global RevPAR increased 6.5 percent in the third quarter, on higher ADR and occupancy. In the U.S. & Canada, RevPAR rose over 7 percent, with broad-based growth across customer segments and chain scales.”
Anthony Capuano, President and Chief Executive Officer
“Our global scale, compelling portfolio of brands, industry-leading Marriott Bonvoy loyalty program and dedicated associates, together with our robust development pipeline and disciplined execution, give us confidence in our ability to deliver sustainable, long-term growth.”
Anthony Capuano, President and Chief Executive Officer
Vertical Data Inc. announced it intends to issue shares of common stock in a private placement transaction for gross proceeds of approximately $4.2 million. The company also disclosed a non-binding term sheet for a GPU-as-a-Service arrangement with a cloud provider involving 16,000 NVIDIA GPUs with a potential contract value of $2.8 billion.
Information Services Group (ISG) reported Q3 2026 revenues of $65.1 million, up 4.4% year-over-year, driven by significant growth in Asia Pacific and AI-related revenues. The company achieved its highest quarterly margin in four years at 15.4% and generated $12.3 million in cash from operations, the highest in five years.
Term
Q3 2026
“ISG delivered a robust financial performance in the third quarter, with strong cash generation, expanding margins and solid revenue growth. Revenue in the quarter was driven by a return to growth in Asia Pacific, up 47 percent; AI-related revenues reaching over $30 million for the first time and recurring revenues continuing to build, up 7 percent. This mix of growth helped drive margin expansion to 15.4 percent, our highest quarterly margin in four years. AI is amplifying the value of our portfolio, with research that informs choices, advisory execution that secures outcomes for enterprises and governance that sustains value. We are well-positioned to close out an outstanding 2026 and continue our momentum into the new year.”
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
Tempus AI reported record Q3 2026 revenue of $411.5 million, a 23% year-over-year increase driven by strong growth in its Oncology and Data & Applications segments. The company narrowed its net loss to $14.9 million and raised its full-year 2026 revenue guidance to a range of $1.60 billion to $1.605 billion.
Term
Q3 2026
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications. These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”